Testing a New Medication (Etrinabdiona) for Leg Circulation disease: A Study of Safety, Tolerability and Preliminary Efficacy

Overview

Sponsor-declared trial summary

Key facts

Sponsor

Vivacell Biotechnology Espana S.L.

Participant type

Patients

Age range

18-64 years, 65+ years

Gender

Male and Female

Therapeutic area

Diseases [C] - Cardiovascular Diseases [C14]

Trial duration

completed 19 May 2026

Decision date (initial)

2024-05-13

Transition trial

No

Low-intervention

No

Rare-disease indication

No

Vulnerable population

No

Funding sources

Vivacell Biotechnology España S.L.U.

Trial design

CTIS Part I — objectives, methods, condition coding

Main objective

Scope: Efficacy, Pharmacokinetic, Safety

Safety and tolerability of Etrinabdione in patients with PAD administered for up to 12 months

Secondary objectives 3

1. Effect of Etrinabdione administered to patients with PAD for up to 12 months on, Vascularization, Clinical improvement, Quality of life and Tissue oxygenation; Hemodynamic, Stenosis,
2. Etrinabdione pharmacokinetics (pre-dose and 3 hours post dose) at Day 1 and months 1, 3, 6, 12 and EOS;
3. Selected drug and/or disease-related vascular, and inflammatory biomarkers at Day 1 and months 1, 3, 6,12 and EOS;

Conditions and MedDRA coding

Peripheral Arterial Disease

Study design 1 period

Eligibility criteria

Principal inclusion / exclusion criteria as submitted by sponsor

Inclusion criteria 8

1. Male and female adults aged ≥ 50 to ≤ 85 years at the time of consent
2. Willing and able to provide informed consent and capable of understanding and complying with the protocol;
3. Subjects classified as critical limb ischemia (CLI) Rutherford Category 2 or 3 (moderate or severe) claudication (Appendix 1);
4. Diabetes mellitus type 2
5. Glycosylated haemoglobin (HbA1c) < 9%
6. In case of treatment for PAD, the subject is controlled on medical therapy indicated for CLI (unless there is a documented contraindication or intolerance)
7. A female patient is eligible to participate if she is not pregnant, not breastfeeding, and at least 1 of the following conditions applies: a) Not of childbearing potential, defined as surgically sterile (documented hysterectomy, bilateral salpingectomy, or bilateral oophorectomy) or postmenopausal (no menses for 12 months without an alternative medical cause) b) Of childbearing potential and agrees to use a highly effective method of contraception consistently as defined in this protocol during the treatment period and for at least 28 days after the last dose of study treatment
8. A male patient with a female partner of childbearing potential is eligible to participate if he agrees to use acceptable contraception during the treatment period and for approximately 90 days after the last dose of study treatment and refrains from donating sperm during this period

Exclusion criteria 22

1. CLI Rutherford other than Category 2 or 3
2. Planned surgical or endovascular revascularization on the index leg within the next 12 months;
3. Uncontrolled or untreated proliferative retinopathy;
4. Failed surgical or endovascular revascularization on the index leg within 10 days prior to screening
5. Amputation at or above the talus on the index l
6. Planned major amputation within the first month after randomiz
7. On the index leg, use of concomitant wound treatments not currently approved for ischemic wound-healing within 30 days prior to screening or plans to initiate new treatments (not standard of care) to the index leg during the trial
8. Blood clotting disorder not caused by medication (e.g., thrombophilia)
9. Severe hypertension according to the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (stage 2 hypertension: Systolic blood pressure ≥ 160 mmHg or diastolic blood pressure ≥ 100 mmHg)
10. Evidence of moderate to severe hepatocellular dysfunction according to the Investigator
11. Positive test for human immunodeficiency virus 1 (HIV 1), HIV 2, hepatitis B virus (HBV), hepatitis C virus (HCV) or Treponema Pallidum
12. Subjects who may not be healthy enough to successfully complete all protocol requirements, or who are not expected to survive more than 12 months, or in whom results may be particularly difficult to assess, as assessed by the Investigator: For example: Concurrent severe congestive heart failure (New York Heart Association Classes III and IV); Life-threatening ventricular arrhythmias, unstable angina (characterized by increasingly frequent episodes with modest exertion or at rest, worsening severity, and prolonged duration), and/or myocardial infarction within four weeks before screening; Coronary artery bypass grafting or percutaneous coronary intervention within one month before screening; A renal and/or carotid revascularization procedure within one month of screening; Transient ischemic attack within three months prior to screening; Deep vein thrombosis within three months prior to screening; Subjects with immunocompromised conditions, organ transplant recipients and/or subjects in need of immunosuppressive therapy; Neurological dementia (i.e., Alzheimer’s Disease)
13. Current or prior participation in a clinical trial within 3 months of first investigational product administration or 5 times the half-life of the prior investigational product, whichever is longer
14. Concomitant medication that could cause drug-interactions as defined in the appropriate section of the protocol, (Section 6.7).
15. History of malignancy with the following exceptions: basal cell carcinoma, cutaneous squamous cell carcinoma or cervical carcinoma in situ resolved > 1 year prior to screening
16. Use of cannabis products up to 28 days prior to dosing and during the study
17. Suspected hypersensitivity to cannabinoids or any of the inactive ingredients of Etrinabdione Oral Solution: corn oil and Maisine® CC
18. Confirmed diagnosis of albinism
19. Moderate or severe drug or alcohol abuse within the past year and during the study (as defined by the investigator)
20. Female participant is pregnant or breastfeeding or plans to become pregnant or begin breastfeeding at any point during the study and for 28 days after last investigational product administration. Not willing to follow the guidance for contraception methods as per protocol
21. Male participant does not agree to use acceptable contraception during the treatment period and for approximately 90 days after the last dose of study treatment or planning to donate sperm during the same period
22. Any finding that in the view of the investigator would compromise the safety of the patient or affect his/her ability to adhere to the protocol visit schedule or fulfil study requirements including self-administration

Endpoints

Primary and secondary outcome measures (English text)

Primary endpoints 1

1. Incidence and severity of treatment-emergent adverse events (TEAEs) from baseline to the end of the study

Secondary endpoints 8

1. Changes from baseline for Vascularization: Angio-CT
2. Changes from baseline for Hemodynamic: ankle/brachial Index
3. Changes from baseline for Stenosis: doppler ultrasound
4. Changes from baseline for Quality of life: VascuQoL-6 questionnaire
5. Changes from baseline for Tissue oxygenation: transcutaneous oximetry (TcPO2)
6. Changes from baseline for Etrinabdione plasma levels (pre-dose and 3 hours post dose) at Day 1 and months 1, 3, 6,12, and EOS
7. Changes from baseline for selected drug and/or disease-related vascular and inflammatory biomarkers at Day 1 and months 1, 3, 6, 12, and EOS
8. Changes from baseline for: Clinical improvement: absolute claudication time

Investigational products

Investigational medicinal products (IMPs), comparators, placebo, auxiliary

Test 1

Sponsors and contacts

Sponsor organisations, regulatory contacts, third parties

Vivacell Biotechnology Espana S.L.

Sponsor organisation

Vivacell Biotechnology Espana S.L.

Address

Edificio Centauro, Calle Astronoma Cecilia Payne Sn Calle Astronoma Cecilia Payne Sn

City

Cordoba

Postcode

14014

Country

Spain

Scientific contact point

Organisation

Vivacell Biotechnology Espana S.L.

Contact name

Maria del Mar Municio

Public contact point

Organisation

Vivacell Biotechnology Espana S.L.

Contact name

Valeriano Díaz

Third parties 1

Locations

1 EU/EEA country · 1 investigational sites

By country

Investigational sites

Results and documents

Annex IV summary of results, Annex V layperson summary, and all documents registered in CTIS for this trial

Documents 9 files

Public protocol annexes, IB summaries, regulatory submissions and post-authorisation documents registered in CTIS.

Application history

3 submissions — initial application plus substantial / non-substantial modifications